You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Botulinum Toxin Plantibodies

    SBC: Planet Biotechnology Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective countermeasure to defend the American public from a bioterrorist attack by botulinum toxin. We aim to be the manufacturer of an antibody or antibody mixture, derived form transgenic plants; that win effectively neutralize botulinum toxin and will supp ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB

    SBC: CELLF-BIO LLC            Topic: 300

    Project Summary/Abstract:Fecal incontinence (FI), the involuntary soiling of various amounts of liquid and solid stool, is often devastating from a social, psychological, and hygiene perspective. Men and women suffer from FI equally with a range of 2 - 6% in people aged 20 - 30 years. The prevalence increases to over 15% in people older than 70 years1. FI may result from an isolated or combined lo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Sample Processing Cartridges for Rapid PCR TB Detection

    SBC: CEPHEID            Topic: N/A

    DESCRIPTION (provided by applicant): Cepheid Inc and the New Jersey Medical School have developed an assay system that integrates sample processing and real-time PCR diagnosis into a single, hands free process. During the successful completion of a phase I STTR application we demonstrated that this system simultaneously detect the presence of Mycobacterium tuberculosis (TB) and diagnose rifampin r ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Neuroprotection in Stroke Drug Development

    SBC: ARMAGEN TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 800,000 persons in the U.S. suffer an acute stroke each year. There presently is no neuroprotective agent that can be given to patients with acute stroke, and stroke is the third leading cause of death. The costs for rehabilitation of patients that survive a stroke is greater than $40 billion per year in the U.S. The reason that an effective neur ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Therapy for Pulmonary Anthrax

    SBC: Planet Biotechnology Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): We have shown that a plant-produced recombinant protein derived from a human anthrax toxin receptor protein and human IgG (an immunoadhesin), neutralizes anthrax lethal toxin in cell culture assays. In this project we will show the effectiveness of this immunoadhesin in vivo, both against purified toxin and in an animal model of pulmonary anthrax (infection w ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Spectroscopic Localization of Breast Cancer

    SBC: SPECTROS CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): This Multi-Center Phase II R44 Competing Renewal addresses the late diagnosis of breast cancer. With rare treatment exceptions (such as Tamoxifen and Herceptin), the long-term stage-specific mortality after breast cancer diagnosis has not appreciably changed over the past 50 years. Recently, many have concluded that the single major factor in improved survival ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Improved Diagnosis of Kaposi's Sarcoma-Associated Herpesvirus Infection

    SBC: EPIPHANY BIOSCIENCES, INC.            Topic: R

    Project Summary Abstract Kaposiandapos s sarcoma herpes virusKSHVis an oncovirus that causes several cancers including Kaposiandapos s sarcomaKSIt is estimated thattoof U Sblood donors have been infected with KSHVyet in some high risk populations such as homosexual menprevalence is as high asIn spite of HAARTKS remains the second most common AIDSassociated malignancyA third of AIDS KS cases now ar ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Highly sensitive measurement of cTnI without a reader: the Xip solution

    SBC: SILICON BIODEVICES, INC.            Topic: NHLBI

    Project Summary Acute myocardial infarction (MI) is the biggest killer in the western world and is the cause of death for nearly 500,000 Americans each year. The symptoms of MI can be vague and non- specific and 7 million adults present to hospital Emergency Departments in the US each year with suspected MI. Advances in cardiac biomarkers have had a large impact on the diagnosis, risk stratificati ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. MR191_An Immunoprotectantfor Marburg Virus

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: NIAID

    PROJECT SUMMARY Mapp BiopharmaceuticalIncMappis developing antibody based therapeutics to treat a number of infectious agentsincluding some of the most dangerous known to manthe filovirusesMarburg virus is a filovirus endemic to Africa and causes an often lethal hemorrhagic feverPresently there are no approved vaccines or therapeutics to treat Marburg virus infections and this remains a major unme ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: R

    PROJECT SUMMARYWhile modern HIV combination therapy has transformed HIV into a manageable chronic infection for many patientsHIV AIDS remains a formidable global epidemicDespite the effectiveness of combining drugs from different classesside effects and drug resistance remain serious concerns for these life long therapiesThusthere is an enduring need for novel HIV inhibitors with new mechanisms of ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government